Review





Similar Products

end hole catheter  (Vygon Company)
86
Vygon Company end hole catheter
End Hole Catheter, supplied by Vygon Company, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/end hole catheter/product/Vygon Company
Average 86 stars, based on 1 article reviews
end hole catheter - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
terminal deoxynucleotidyl transferase dutp nick end labeling tunel assay  (Elabscience Biotechnology)
86
Elabscience Biotechnology terminal deoxynucleotidyl transferase dutp nick end labeling tunel assay
BDNF overexpression reduces neuronal apoptosis and axonal necrosis. (A) Immunofluorescence was employed to detect 5-HT-positive axons on day 28 post-spinal cord injury. Scale bar: 500 μm. 5-HT: white. (B–H) Microglial BDNF overexpression inhibits neuronal apoptosis following spinal cord injury. In B, scale bar: 50 μm, nuclei: blue, <t>TUNEL:</t> green. In F, scale bar: 100 μm, nuclei: blue, NeuN: red. One-way analysis of variance with Bonferroni post hoc test (C–E, G, H). Error bars in all figures represent SD. *** P < 0.001. In A–H, C57BL/6J mice were used in the sham and SCI groups, and CX3:BDNF mice were used in the SCI-CX3:BDNF group, and there were six mice in each group. BDNF: Brain-derived neurotrophic factor; DAPI: 4′,6-diamidino-2-phenylindole; 5-HT: 5-hydroxytryptamine; NeuN: neuronal nuclei; SCI: spinal cord injury; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
Terminal Deoxynucleotidyl Transferase Dutp Nick End Labeling Tunel Assay, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/terminal deoxynucleotidyl transferase dutp nick end labeling tunel assay/product/Elabscience Biotechnology
Average 86 stars, based on 1 article reviews
terminal deoxynucleotidyl transferase dutp nick end labeling tunel assay - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
terminal deoxynucleotidyl transferase dutp nick end labeling tunel staining  (Beyotime)
86
Beyotime terminal deoxynucleotidyl transferase dutp nick end labeling tunel staining
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
Terminal Deoxynucleotidyl Transferase Dutp Nick End Labeling Tunel Staining, supplied by Beyotime, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/terminal deoxynucleotidyl transferase dutp nick end labeling tunel staining/product/Beyotime
Average 86 stars, based on 1 article reviews
terminal deoxynucleotidyl transferase dutp nick end labeling tunel staining - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
rv end systolic pressure  (CardioMEMS Inc)
86
CardioMEMS Inc rv end systolic pressure
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
Rv End Systolic Pressure, supplied by CardioMEMS Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rv end systolic pressure/product/CardioMEMS Inc
Average 86 stars, based on 1 article reviews
rv end systolic pressure - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
end product  (Bruker Corporation)
86
Bruker Corporation end product
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
End Product, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/end product/product/Bruker Corporation
Average 86 stars, based on 1 article reviews
end product - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
tdt mediated dutp nick end labelling assay  (Roche)
86
Roche tdt mediated dutp nick end labelling assay
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
Tdt Mediated Dutp Nick End Labelling Assay, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tdt mediated dutp nick end labelling assay/product/Roche
Average 86 stars, based on 1 article reviews
tdt mediated dutp nick end labelling assay - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
end effector robot amadeo  (Tyromotion GmbH)
86
Tyromotion GmbH end effector robot amadeo
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
End Effector Robot Amadeo, supplied by Tyromotion GmbH, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/end effector robot amadeo/product/Tyromotion GmbH
Average 86 stars, based on 1 article reviews
end effector robot amadeo - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
end effector type robotic device  (Tyromotion GmbH)
86
Tyromotion GmbH end effector type robotic device
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
End Effector Type Robotic Device, supplied by Tyromotion GmbH, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/end effector type robotic device/product/Tyromotion GmbH
Average 86 stars, based on 1 article reviews
end effector type robotic device - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
tdt mediated dutp nick end labelling tunel staining  (Roche)
86
Roche tdt mediated dutp nick end labelling tunel staining
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
Tdt Mediated Dutp Nick End Labelling Tunel Staining, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tdt mediated dutp nick end labelling tunel staining/product/Roche
Average 86 stars, based on 1 article reviews
tdt mediated dutp nick end labelling tunel staining - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier
proximal end  (Olympus)
86
Olympus proximal end
Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative <t>TUNEL</t> and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal <t>deoxynucleotidyl</t> <t>transferase</t> <t>dUTP</t> nick end labeling.
Proximal End, supplied by Olympus, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proximal end/product/Olympus
Average 86 stars, based on 1 article reviews
proximal end - by Bioz Stars, 2025-05
86/100 stars
  Buy from Supplier

Image Search Results


BDNF overexpression reduces neuronal apoptosis and axonal necrosis. (A) Immunofluorescence was employed to detect 5-HT-positive axons on day 28 post-spinal cord injury. Scale bar: 500 μm. 5-HT: white. (B–H) Microglial BDNF overexpression inhibits neuronal apoptosis following spinal cord injury. In B, scale bar: 50 μm, nuclei: blue, TUNEL: green. In F, scale bar: 100 μm, nuclei: blue, NeuN: red. One-way analysis of variance with Bonferroni post hoc test (C–E, G, H). Error bars in all figures represent SD. *** P < 0.001. In A–H, C57BL/6J mice were used in the sham and SCI groups, and CX3:BDNF mice were used in the SCI-CX3:BDNF group, and there were six mice in each group. BDNF: Brain-derived neurotrophic factor; DAPI: 4′,6-diamidino-2-phenylindole; 5-HT: 5-hydroxytryptamine; NeuN: neuronal nuclei; SCI: spinal cord injury; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling.

Journal: Neural Regeneration Research

Article Title: Microglia overexpressing brain-derived neurotrophic factor promote vascular repair and functional recovery in mice after spinal cord injury

doi: 10.4103/NRR.NRR-D-24-00381

Figure Lengend Snippet: BDNF overexpression reduces neuronal apoptosis and axonal necrosis. (A) Immunofluorescence was employed to detect 5-HT-positive axons on day 28 post-spinal cord injury. Scale bar: 500 μm. 5-HT: white. (B–H) Microglial BDNF overexpression inhibits neuronal apoptosis following spinal cord injury. In B, scale bar: 50 μm, nuclei: blue, TUNEL: green. In F, scale bar: 100 μm, nuclei: blue, NeuN: red. One-way analysis of variance with Bonferroni post hoc test (C–E, G, H). Error bars in all figures represent SD. *** P < 0.001. In A–H, C57BL/6J mice were used in the sham and SCI groups, and CX3:BDNF mice were used in the SCI-CX3:BDNF group, and there were six mice in each group. BDNF: Brain-derived neurotrophic factor; DAPI: 4′,6-diamidino-2-phenylindole; 5-HT: 5-hydroxytryptamine; NeuN: neuronal nuclei; SCI: spinal cord injury; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling.

Article Snippet: A terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed at 24 hours after SCI (TUNEL kit, Elabscience, Wuhan, China.

Techniques: Over Expression, Immunofluorescence, TUNEL Assay, Derivative Assay

Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative TUNEL and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling.

Journal: Neural Regeneration Research

Article Title: Neuroserpin alleviates cerebral ischemia-reperfusion injury by suppressing ischemia-induced endoplasmic reticulum stress

doi: 10.4103/NRR.NRR-D-24-00044

Figure Lengend Snippet: Secreted neuroserpin ameliorates cell death in cultured cortical neurons. (A) Schematic of the experiment: cell lysates and media of cortical neurons (7 DIV) were collected separately and analyzed individually for NSP levels after 4 hours of OGD. (B) Representative western blot images showing the cellular and secreted levels of NSP. (C) Quantifications of NSP protein levels in cell lysate or medium from primary cortical neurons after 4 hours of OGD by Western blot assay ( n = 6). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (D) Quantifications of the cellular NSP mRNA level in cell lysate from primary cortical neurons after 4 hours of OGD by quantitative polymerase chain reaction ( n = 7). **** P < 0.0001, OGD 4 h vs . control, unpaired t -test. (E) Neuroserpin mRNA levels in brain tissues of sham and MCAO mice by quantitative polymerase chain reaction ( n = 3 mice per group). ** P < 0.01, control vs . MCAO, unpaired t -test. (F) A diagram showing the conditional medium treatment procedure. Conditioned medium was collected from normal neurons of the same stage (7 DIV) and added to OGD-injured neurons for the reperfusion phase. To neutralize NSP in the medium, anti-NSP antibody (α-NSP Ab; 50 ng for 20,000 cells) was added in the conditional medium. (G) Cell viability was measured by MTT assay in OGD/R neurons cultured in conditioned medium with or without α-NSP Ab ( n = 3). ** P < 0.01, OGD/R vs. control; # P < 0.05, OGD/R + conditioned medium vs . OGD/R; $ P < 0.05, OGD/R + conditioned medium + α-NSP Ab vs. OGD/R + conditioned medium, unpaired t -test. (H) A diagram showing the recombinant NSP treatment procedure. NSP (1−20 ng/mL) was added to neurons 4 hours before OGD and during OGD and after reperfusion. (I) Cell viability of neurons treated with different concentrations of NSP was determined by MTT assay ( n = 4). **** P < 0.0001, OGD/R vs. control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (J) Representative images of live and dead neurons, treated with 20 ng/mL NSP, measured by the live and death cell assay. Scale bar: 200 µm. (K) Quantification of the percentage of dead cells ( n = 3). *** P < 0.001, OGD/R vs . control; ## P < 0.01, OGD/R + NSP vs. OGD/R, unpaired t -test. (L) A diagram showing the experimental procedure: NSP (50 and 100 ng/mL) was added to neurons immediately after OGD. (M) Cell viability of neurons treated with different concentrations of NSP were determined by MTT assay ( n = 3). **** P < 0.0001, OGD/R vs . control; # P < 0.05, OGD/R + NSP vs . OGD/R, unpaired t -test. (N) Representative TUNEL and DAPI staining in OGD/R-injured neurons treated with NSP (20 and 100 ng/mL). Scale bar: 100 µm. (O) Number of TUNEL-positive cells in each group was quantified and normalized to that of the control group ( n = 3). ** P < 0.01, OGD/R vs. control; ## P < 0.01, OGD/R + NSP vs . OGD/R, unpaired t -test. Data are shown as mean ± SEM. α-NSP Ab: Anti-NSP antibody; DAPI: 4′,6-diamidino-2-phenylindole; DIV: day in vitro ; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MCAO: middle cerebral artery occlusion; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; NSP: neuroserpin; OGD: oxygen-glucose deprivation; OGD/R: oxygen-glucose deprivation/reperfusion; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling.

Article Snippet: Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed using a One Step TUNEL Apoptosis Assay Kit (Beyotime Biotechnology, Shanghai, China, Cat# C1088) following the manufacturer’s instructions.

Techniques: Cell Culture, Western Blot, Control, Real-time Polymerase Chain Reaction, MTT Assay, Recombinant, TUNEL Assay, Staining, In Vitro